ROS1 and non-small cell lung carcinoma: Bradycardia was both reported in the phase 3 study (PROFILE 1014) in ALK-positive NSCLC (Solomon et al., 2016) and the phase 1 study (PROFILE 1001) in ROS1-rearranged advanced NSCLC (Shaw et al., 2019).